Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 9:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 1,891 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostate Cancer Patients Clear all
Completed Not applicable Interventional

Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients

NCT04604158
View directory record Official record
Conditions
Cancer, Cancer Metastatic, Neoplasms, Breast Cancer, Lung Cancer, Glioblastoma, Prostate Cancer, Gynecologic Cancer, Colorectal Cancer, Sarcoma, Kidney Cancer, Bladder Cancer, Lymphoma, Leukemia, Head and Neck Cancer, Pancreas Cancer, Multiple Myeloma, Anxiety, Social Isolation, Stress, Loneliness, Melanoma, Uterine Cancer
Interventions
Elly Mobile Phone Application
Behavioral
Lead sponsor
Gillian Gresham
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Oct 31, 2026, 9:37 PM EDT
Completed Phase 1 Interventional

A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies

NCT02740985
View directory record Official record
Conditions
Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC), Colorectal Carcinoma (CRC)
Interventions
AZD4635, Durvalumab, Abiraterone Acetate, Enzalutamide, Oleclumab, Docetaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
17
States / cities
Fayetteville, Arkansas • Fresno, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated May 26, 2023 · Synced Oct 31, 2026, 9:37 PM EDT
Not listed Phase 2 Interventional

Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer

NCT01296243
View directory record Official record
Conditions
Prostate Cancer
Interventions
Tesetaxel
Drug
Lead sponsor
Genta Incorporated
Industry
Eligibility
18 Years and older · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Ann Arbor, Michigan • New Brunswick, New Jersey • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2012 · Synced Oct 31, 2026, 9:37 PM EDT
Terminated Phase 2 Interventional Results available

HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer

NCT04264208
View directory record Official record
Conditions
Prostate Cancer
Interventions
68-Ga RM2., 68-Ga PSMA11, PET/MRI
Drug · Device
Lead sponsor
Andrei Iagaru
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Oct 31, 2026, 9:37 PM EDT
Completed No phase listed Observational

Prostate Cancer Patients With Biochemical Recurrence

NCT03527199
View directory record Official record
Conditions
Patients With Prostate Cancer
Interventions
Pelvic CT or MRI + MDP bone scan + or - 18F-NaF PET/CT(SOC)
Diagnostic Test
Lead sponsor
Medhat Osman
Federal
Eligibility
18 Years to 89 Years · Male only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Oct 31, 2026, 9:37 PM EDT
Completed Not applicable Interventional

Effects of GCP on Prostate Cancer.

NCT00269555
View directory record Official record
Conditions
Prostate Cancer
Interventions
Genistein Combined Polysaccharide (GCP)
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
Male only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2010 · Synced Oct 31, 2026, 9:37 PM EDT
Terminated Phase 1 Interventional

177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer

NCT03490838
View directory record Official record
Conditions
Prostatic Neoplasm
Interventions
177Lu-PSMA-R2
Drug
Lead sponsor
Advanced Accelerator Applications
Industry
Eligibility
18 Years and older · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
9
States / cities
Phoenix, Arizona • San Francisco, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 31, 2026, 9:37 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Metabolomic Study for Localized Prostate Cancer

NCT01968538
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation Therapy
Radiation
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2024
U.S. locations
1
States / cities
Arlington, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 31, 2026, 9:37 PM EDT
Completed Phase 3 Interventional Results available

Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI

NCT03404648
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
C-11 choline PET tracer, Gadobutrol, PET/MR scanner
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Oct 31, 2026, 9:37 PM EDT
Completed Phase 2 Interventional

Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer

NCT00039104
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
rebimastat, zoledronic acid, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Oct 31, 2026, 9:37 PM EDT
Completed Phase 1 Interventional Results available

NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine

NCT00199849
View directory record Official record
Conditions
Prostate Cancer, Bladder Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Sarcoma
Interventions
NY-ESO-1 Plasmid DNA Cancer Vaccine
Biological
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 31, 2026, 9:37 PM EDT
Terminated Phase 1 Interventional

Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to Radiation Therapy

NCT00788307
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ad5-CMV-NIS, Liothyronine Sodium, Reverse Transcriptase Polymerase Chain Reaction, laboratory biomarker analysis, Iodine I 131, Iodine I 123
Biological · Drug · Genetic + 2 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 31, 2026, 9:37 PM EDT
Completed Phase 3 Interventional Results available

Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer

NCT03739684
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Recurrent, Prostate Cancer Metastatic
Interventions
18F-DCFPyL, PET/CT Imaging
Drug · Diagnostic Test
Lead sponsor
Progenics Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
13
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 31, 2026, 9:37 PM EDT
Completed Phase 2 Interventional Results available

A Two-dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy

NCT00887458
View directory record Official record
Conditions
Prostate Cancer
Interventions
Itraconazole 200 mg, Itraconazole 300mg
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
4
States / cities
Baltimore, Maryland • Ann Arbor, Michigan • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 31, 2026, 9:37 PM EDT
Completed Phase 2 Interventional

68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer

NCT04050215
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Carcinoma, PSA Level Greater Than Fifty, PSA Progression, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Computed Tomography, Gallium Ga 68-labeled PSMA-11, Positron Emission Tomography, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
937 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Oct 31, 2026, 9:37 PM EDT
Completed Phase 2 Interventional Results available

Study of Acai Juice in Asymptomatic or Minimally Symptomatic Prostate Cancer Patients With Rising PSA

NCT01521949
View directory record Official record
Conditions
Prostate Cancer
Interventions
Acai Juice Product
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 31, 2026, 9:37 PM EDT
Completed No phase listed Observational

A Data Collection Study for Patients With Adenocarcinoma Treated With the MyVaccx Immunotherapy Regimen.

NCT03695835
View directory record Official record
Conditions
Adenocarcinoma
Interventions
Immunotherapeutic Agents, Ablation
Drug · Device
Lead sponsor
Gary Onik MD
Individual
Eligibility
19 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Oct 31, 2026, 9:37 PM EDT
Withdrawn Phase 2 Interventional

Ciprofloxacin Compared to Placebo in Diagnosing Prostate Cancer in Patients Undergoing Prostate Biopsy

NCT02252978
View directory record Official record
Conditions
Prostate Cancer
Interventions
ciprofloxacin, placebo, quality-of-life assessment, laboratory biomarker analysis
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Salisbury, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 31, 2026, 9:37 PM EDT
Completed Phase 1 Interventional

MRI-Guided Radiation Therapy in Treating Patients Who Have Undergone Surgery to Remove the Prostate

NCT01028885
View directory record Official record
Conditions
Prostate Cancer, Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer
Interventions
radiation therapy treatment planning/simulation, intensity-modulated radiation therapy, image-guided radiation therapy, magnetic resonance imaging, computed tomography
Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 25, 2019 · Synced Oct 31, 2026, 9:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Fish Oil and Green Tea Extract in Preventing Prostate Cancer in Patients Who Are at Risk for Developing Prostate Cancer

NCT00253643
View directory record Official record
Conditions
Precancerous Condition, Prostate Cancer
Interventions
green tea catechin extract, fish oil, placebo
Dietary Supplement · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
21 Years to 120 Years · Male only
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2013
U.S. locations
3
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 31, 2026, 9:37 PM EDT
Terminated Phase 2 Interventional Results available

Docetaxel, Radiation Therapy, and Prednisone in Treating Patients Who Have Undergone Surgery For Prostate Cancer

NCT00348816
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, prednisone, Radical prostatectomy, Radiation therapy
Drug · Procedure · Radiation
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Oct 31, 2026, 9:37 PM EDT
Completed Phase 2 Interventional Results available

Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer

NCT02278185
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
Enzalutamide, leuprolide acetate, goserelin acetate, histrelin acetate, triptorelin, degarelix
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
19 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
2
States / cities
Aurora, Colorado • Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Oct 31, 2026, 9:37 PM EDT
Active, not recruiting Phase 3 Interventional

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT04691804
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Interventions
Fuzuloparib , Abiraterone acetate and Prednisone, Fuzuloparib Placebo， Abiraterone acetate and Prednisone
Drug
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd.
Industry
Eligibility
18 Years and older · Male only
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
17
States / cities
Anchorage, Alaska • Tucson, Arizona • Rancho Mirage, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2024 · Synced Oct 31, 2026, 9:37 PM EDT
Terminated Phase 2 Interventional Results available

Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer

NCT03999515
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Double-Negative Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone Acetate, Enzalutamide, Erdafitinib
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 31, 2026, 9:37 PM EDT